$Effects of SGLT2 inhibitors on cognitive impairment in elderly inpatients with heart failure with reduced ejection fraction: a prospective cohort study$

Effects of SGLT2 inhibitors on cognitive impairment in elderly inpatients with heart failure with reduced ejection fraction: a prospective cohort study

Abstract Background Heart failure with reduced ejection fraction (HFrEF) and cognitive impairment are significant challenges faced by global healthcare systems. Clinical studies on the impact of drugs for HFrEF on cognitive impairment are very limited. We aimed to assess the effects of regular use o...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jiaying Li, Xiaoyan Wang, Qianwei Zheng, Jing Tian, Huanzhen Chen, Simin Yao
Format:	Article
Language:	English
Published:	BMC 2025-07-01
Series:	BMC Cardiovascular Disorders
Subjects:	Sodium-Glucose cotransporter 2 inhibitor Heart failure with reduced ejection fraction Cognitive impairment Elderly inpatients
Online Access:	https://doi.org/10.1186/s12872-025-04952-w
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long‐term efficacy of SGLT2 inhibitors for elderly patients with acute decompensated heart failure: The OASIS‐HF study
by: Michitaka Amioka, et al.
Published: (2025-02-01)

Heart Failure with Preserved Ejection Fraction in the Indian Context
by: Rajeev Gupta, et al.
Published: (2025-04-01)

Assessing the application of American Heart Association (AHA) guidelines in the management of heart failure with reduced ejection fraction
by: Sima Sobhani Shahri, et al.
Published: (2025-03-01)

The impacts of SGLT2 inhibitors on the mortality of patients with tuberculosis
by: Chung-Shu Lee, et al.
Published: (2025-05-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction
by: Pushpraj Patel, et al.
Published: (2024-12-01)

Sodium-glucose cotransporter 2 inhibitor for the treatment of diabetic nephropathy
by: Kong Ling-li, et al.
Published: (2021-01-01)

Correlation of β-adrenergic reactivity of erythrocyte membranes with clinical characteristics of patients with coronary artery disease and HF with preserved and reduced ejection fraction
by: E. F. Muslimova, et al.
Published: (2025-01-01)

Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study
by: Abdullahi Ahmed Mohamed, et al.
Published: (2025-08-01)

SGLT2 inhibitor upregulates myocardial genes for oxidative phosphorylation and fatty acid metabolism in Gαq-mice
by: Jordan M. Chambers, et al.
Published: (2025-06-01)

EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCE
by: Ramazan Çakmak, et al.
Published: (2025-01-01)

SGLT2 inhibitor administration to two patients with diabetes mellitus with ascites due to cirrhosis
by: Koji Nagayama, et al.
Published: (2025-07-01)

Mechanisms of acute renal injury caused by SGLT-2 inhibitor in patients with diabetes mellitus
by: Gong Yan, et al.
Published: (2021-01-01)

Catestatin as a predictor for cardiac death in heart failure with mildly reduced and preserved ejection fraction
by: Song‐Yun Chu, et al.
Published: (2025-02-01)

Clinical management of heart failure with improved ejection fraction: treatment and maintenance
by: XU Tianyun, et al.
Published: (2025-04-01)

Left atrioventricular coupling index measured by echocardiography in heart failure with preserved ejection fraction
by: Hai Nguyen Ngoc Dang, et al.
Published: (2025-07-01)

Characteristics, outcomes and the necessity of continued guideline-directed medical therapy in patients with heart failure with improved ejection fraction
by: Qin-Fen Chen, et al.
Published: (2025-12-01)

Progress in studies on renal effects and molecular mechanism of SGLT-2 inhibitors
by: XING Bei, et al.
Published: (2020-01-01)

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper
by: João Pedro Ferreira, et al.
Published: (2025-08-01)

Medical Therapy for Heart Failure with Preserved Ejection Fraction
by: Sara Varnado, et al.
Published: (2022-12-01)

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
by: Robert J.H. Miller, et al.
Published: (2022-06-01)

Editorial: Advanced therapeutic strategies and safety profiles in heart failure with reduced ejection fraction: contextualizing recent findings
by: Maria del Carmen Asensio-Lopez, et al.
Published: (2025-04-01)

New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration
by: I. V. Gribkova
Published: (2024-03-01)

Obesity paradox in chronic heart failure with moderately reduced or preserved left ventricular ejection fraction: impact on a prognosis for patients according to a five-year follow-up
by: P. P. Bidzilya, et al.
Published: (2023-07-01)

SGLT2 inhibitors in lupus nephritis: a multicentric study in Latin America
by: José L. Daza, et al.
Published: (2025-04-01)

Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study
by: Yinge Zhan, et al.
Published: (2025-02-01)

Predictors of sustained reverse remodelling in patients with heart failure with reduced ejection fraction
by: Silas Ramos Furquim, et al.
Published: (2025-06-01)

Factors influencing early renal function changes after SGLT2 inhibitors use and its long-term prognosis: a real-world retrospective study
by: Bing Xie, et al.
Published: (2025-12-01)

A meta-analysis and review on the effectiveness and safety of renal denervation in managing heart failure with reduced ejection fraction
by: Quanbin Su, et al.
Published: (2024-12-01)

Circulating Cell-Free Nuclear DNA Predicted an Improvement of Systolic Left Ventricular Function in Individuals with Chronic Heart Failure with Reduced Ejection Fraction
by: Tetiana Berezina, et al.
Published: (2024-10-01)

Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM)
by: K. Tobe, et al.
Published: (2021-07-01)

Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
by: S. N. Tereshchenko, et al.
Published: (2020-06-01)

Prognostic significance of NT-proBNP and sST2 in patients with heart failure with preserved and mildly reduced ejection fraction
by: V. I. Podzolkov, et al.
Published: (2023-10-01)

Early hemodynamic impact of SGLT2 inhibitors in overweight cardiometabolic heart failure: beyond fluid offloading to vascular adaptation– a preliminary report
by: Nadia Salerno, et al.
Published: (2025-03-01)

Influence of intravenous ferric carboxymaltose on non-invasive parameters of left ventricular myocardial work in patients with heart failure with reduced ejection fraction
by: Zh. D. Kobalava, et al.
Published: (2023-02-01)

ALDH2 mediates the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on improving cardiac remodeling
by: Han Liu, et al.
Published: (2024-10-01)

Association of visceral adiposity index (VAI) with prognosis in patients with metabolic syndrome and heart failure with reduced ejection fraction
by: Meiyin Wu, et al.
Published: (2025-03-01)

Liver function effects of SGLT2 inhibitor and GLP‐1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study)
by: Daisuke Tsuriya, et al.
Published: (2025-07-01)

Prevalence of anemia, its associated factors, and impact on quality of life among heart failure with reduced ejection fraction outpatients at the university of Gondar hospital, Ethiopia
by: Daniel Belay Agonafir, et al.
Published: (2025-07-01)

Prediction model of rehospitalization and mortality in heart failure patients with preserved and mildly reduced ejection fraction: the AD2NNER risk score
by: Flavia-Mihaela Stoiculescu, et al.
Published: (2025-07-01)